Pleural fluid neopterin levels in tuberculous pleurisy

Basit Öğe Kaydı
dc.contributor.authorCok, Gursel
dc.contributor.authorParildar, Zuhal
dc.contributor.authorBasol, Gunes
dc.contributor.authorKabaroglu, Ceyda
dc.contributor.authorBayindir, Ulku
dc.contributor.authorHabif, Sara
dc.contributor.authorBayindir, Ova
dc.date.accessioned2019-10-27T19:33:03Z
dc.date.available2019-10-27T19:33:03Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: Neopterin is produced by stimulated macrophages under the influence of gamma interferon of lymphocyte origin. It is regarded as a biochemical marker of cell-mediated immune response. This study was designed to assess the diagnostic value of pleural fluid neopterin levels in tuberculous pleurisy in comparison with adenosine deaminase activity. Design and methods: Pleural fluid adenosine deaminase (ADA) activity and neopterin levels were measured in 16 patients with tuberculous pleurisy (TP) and 19 patients with malignant pleurisy (MP). ADA activity was determined by a colorimetric method, whereas neopterin levels were determined by a reversed-phase liquid chromatography technique. All values were given as median (min-max). Results: The mean age was 45.43 +/- 20.39 years in the TP group and 60.42 +/- 11.02 years in the MP group (p = 0.026). The median pleural fluid ADA activity was 51.75 U/L (3.50-62.40 U/L) in the TP group and was 2.30 U/L (1-8.20 U/L) in the MP group. The difference was statistically significant (p < 0.001). The median pleural fluid neopterin levels were 13.15 nmol/L (1.86-59.50 nmol/L) and 2.44 nmol/L (0.92-27.60 nmol/L) in the TP group and the NIP group, respectively (p 0.021). In order to evaluate the diagnostic value of pleural fluid neopterin concentrations, receiver-operating-characteristic curve analysis was performed. Conclusion: Pleural fluid neopterin concentration is significantly higher in TP when compared to MP, however when compared, its clinical use as a diagnostic marker is not valuable as ADA. (c) 2007 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clinbiochem.2007.04.009en_US
dc.identifier.endpage880en_US
dc.identifier.issn0009-9120
dc.identifier.issue12en_US
dc.identifier.pmid17531216en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage876en_US
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2007.04.009
dc.identifier.urihttps://hdl.handle.net/11454/39406
dc.identifier.volume40en_US
dc.identifier.wosWOS:000248465100008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofClinical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectneopterinen_US
dc.subjecttuberculous pleurisyen_US
dc.subjectmalignant pleurisyen_US
dc.titlePleural fluid neopterin levels in tuberculous pleurisyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu